8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
A critical examination of the UKPDS 34 trial's enrollment biases, statistical caveats, generalizability gaps, and what post-publication commentary revealed about metformin's landmark evidence base.
A deep-dive into the UKPDS 34 trial design, randomization scheme, endpoint definitions, statistical methods, and how each methodological choice shapes the interpretation of metformin's 32% risk reduction in overweight type 2 diabetes.
Deep-dive into the health-economic modeling behind UKPDS 34, examining metformin's cost per QALY, payer-coverage rationale, and real-world pricing for overweight patients with type 2 diabetes.
Deep dive into the UKPDS 34 post-trial monitoring program, the legacy effect of early metformin therapy, and long-term safety and efficacy data that emerged after the original 1998 publication.
Complete breakdown of UKPDS 34 metformin outcomes including effect sizes, confidence intervals, secondary endpoints, and the 10-year time-course pattern in overweight type 2 diabetes.
Deep-dive into UKPDS 34 pre-specified and post-hoc subgroup analyses for metformin in overweight type 2 diabetes, examining responses by age, sex, BMI, and baseline biomarkers.
A deep-dive into UKPDS 34, the 1998 landmark trial that proved metformin reduces diabetes complications and death in overweight patients with type 2 diabetes, establishing it as first-line therapy worldwide.
A deep-dive into how UKPDS 34 reshaped metformin prescribing, which guidelines shifted, and what the trial's design means for patients who look nothing like the original cohort.